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Abstract
Bacterial contact-dependent growth inhibition (CDI) is mediated by the CdiB/CdiA family of two-partner secretion proteins.
CDI systems deploy a variety of distinct toxins, which are contained within the polymorphic C-terminal region (CdiA-CT) of
CdiA proteins. Several CdiA-CTs are nucleases, suggesting that the toxins are transported into the target cell cytoplasm to
interact with their substrates. To analyze CdiA transfer to target bacteria, we used the CDI system of uropathogenic
Escherichia coli 536 (UPEC536) as a model. Antibodies recognizing the amino- and carboxyl-termini of CdiAUPEC536 were used
to visualize transfer of CdiA from CDIUPEC536+ inhibitor cells to target cells using fluorescence microscopy. The results
indicate that the entire CdiAUPEC536 protein is deposited onto the surface of target bacteria. CdiAUPEC536 transfer to bamA101
mutants is reduced, consistent with low expression of the CDI receptor BamA on these cells. Notably, our results indicate
that the C-terminal CdiA-CT toxin region of CdiAUPEC536 is translocated into target cells, but the N-terminal region remains at
the cell surface based on protease sensitivity. These results suggest that the CdiA-CT toxin domain is cleaved from
CdiAUPEC536 prior to translocation. Delivery of a heterologous Dickeya dadantii CdiA-CT toxin, which has DNase activity, was
also visualized. Following incubation with CDI+ inhibitor cells targets became anucleate, showing that the D.dadantii CdiA-
CT was delivered intracellularly. Together, these results demonstrate that diverse CDI toxins are efficiently translocated
across target cell envelopes.
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Introduction
Contact-dependent growth inhibition (CDI) is a mechanism
that allows Gram-negative bacteria to inhibit the growth of
neighboring bacteria upon direct cell-to-cell contact [1–3]. CDI is
mediated by the CdiB/CdiA family of two-partner secretion
proteins, which are found in many Gram-negative bacteria
including a, b, and c-proteobacteria. CdiB is a predicted b-barrel
protein required for export of the CdiA effector protein across the
outer membrane. CdiA exoproteins are exceptionally large (200–
600 kDa) and are thought to form b-helical filaments several
hundred angstroms in length based on their homology to
filamentous hemagglutinin (FHA) [4]. The current model of
CDI postulates that CdiA filaments extend like quills from
inhibitor cells, allowing the effector protein to engage specific
receptors on the surface of target bacteria. Upon cell-cell contact,
a toxin derived from CdiA is delivered into the target cell to inhibit
growth. Analysis of CdiA proteins from several different bacteria
has shown that the growth inhibitory activity is localized to the
extreme C-terminus [1,5,6], and this region has been collectively
termed ‘‘CdiA-CT’’. Remarkably, the CdiA-CT region is highly
variable between CDI systems, indicating that inhibitor bacteria
deploy a variety of distinct toxins. The CdiA-CT from Escherichia
coli EC93 appears to form pores in the inner membrane because
this toxin dissipates the proton motive force [7]. Other charac-
terized CdiA-CTs have toxic nuclease activities. The CdiA-CT
from uropathogenic E. coli 536 (UPEC 536) is a tRNA anticodon
nuclease [8], and the toxin from the plant pathogen Dickeya dadantii
3937 has avid DNase activity when analyzed in vitro [1]. Because
CDI systems target bacteria, CDI+ inhibitor cells must also
produce an immunity protein (CdiI) to protect themselves from
autoinhibition [2]. CdiI immunity proteins are also highly variable
and specifically bind their cognate CdiA-CT to block toxin
activity, but they provide no protection from the CDI toxins
deployed by other bacteria [1,5]. Thus, CDI systems form
a network of toxin/immunity proteins that function in bacterial
growth competition.
Because CDI systems inhibit growth by either degrading nucleic
acids or disrupting the bacterial inner membrane, CdiA-CT toxins
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must be delivered across the target cell envelope. The mechanisms
of toxin translocation remain unknown, but genetic approaches
have identified two envelope proteins that may facilitate the
process for the E. coli EC93 CDI system. Selections for CDIEC93
resistant E. coli mutants led to the isolation of a single transposon
insertion in the promoter region of bamA (bamA101) and several
different disruptions of the acrB coding sequence [9]. BamA is an
essential outer membrane protein that forms the core of the b-
barrel assembly complex in Gram-negative bacteria [10–14]. The
bamA101 mutation decreases BamA surface expression approxi-
mately five-fold and confers partial resistance to EC93 inhibitor
cells [9]. CDI+ inhibitor cells bind to bamA101 mutants less
efficiently than wild-type bamA+ cells and E. coli target cells are
protected from CDI by pre-incubation with anti-BamA antibodies
[9]. Together, these observations argue that BamA is the CDI
receptor in E. coli and suggest that it may also serve as a conduit for
CdiA-CT transport across the outer membrane. AcrB is a trimeric
inner membrane protein that functions with AcrA and TolC as
a multi-drug efflux pump [15,16]. TolC is a periplasm-spanning
porin that is parasitized to translocate a subset of colicin toxins
[17]. However, deletion of either acrA or tolC genes has no effect on
CDIEC93 resistance [9], indicating that the role of AcrB in
CDIEC93 resistance is distinct from its efflux function and the
colicin import pathway. AcrB is also required for growth inhibition
when the isolated CdiA-CTEC93 domain is produced inside E. coli
cells [7]. This latter finding suggests that AcrB facilitates toxin
insertion into the inner membrane from both periplasmic and
cytoplasmic compartments. Such a function implies that AcrB is
specific to the EC93 CDI pathway, and indeed acrB mutants are
not resistant to CDI mediated by UPEC 536. Based on these
observations, it appears that the various CdiA-CT toxins could
each exploit distinct pathways to enter target cells.
Here, we use cell biological approaches to visualize CDI toxin
delivery into target bacteria. Immunofluorescence microscopy
using antibodies to antigens at the N- and C-termini of
CdiAUPEC536 suggests that the entire CdiA protein is transferred
to the surface of target cells during growth inhibition. CdiA
transfer is proportional to the level of BamA receptor on target
cells. CdiA-CTUPEC536 antigen is detected in the cytoplasm of
target cells, suggesting that the toxin is cleaved from full-length
CdiA prior to translocation of the CdiA-CT. Furthermore, we
demonstrate the translocation of a heterologous CDI toxin from
Dickeya dadantii 3937 into E. coli target cells. We replaced the CdiA-
CT of CdiAEC93 with the CdiA-CT393722 DNase domain to create
a chimeric effector protein, and monitored toxin delivery by
staining target cell DNA with DAPI. Target bacteria lost DAPI
staining in response to co-culture with chimeric CDI393722
inhibitor cells, consistent with the complete degradation of their
genomes. Together, these results demonstrate that diverse CDI
toxins are efficiently translocated into E. coli cells.
Results
Detection of CdiA on the Surface of Inhibitor Cells
We chose the CDI system from uropathogenic Escherichia coli
536 (UPEC 536) [18] to examine toxin delivery because CdiA-
CTUPEC536 is a tRNase with substrates in the cytosol of target cells.
To facilitate genetic manipulations, we used a cosmid-borne copy
of the UPEC 536 cdiBAI gene cluster, which is sufficient to confer
the inhibitor cell phenotype to CDI- strains of E. coli K-12 [8]. We
introduced a hemagglutinin (HA) peptide epitope near the mature
N-terminus of CdiAUPEC536 for detection by immunofluorescence
(Fig. 1A). Additionally, we raised polyclonal antiserum against the
CdiA-CTUPEC536 toxin region. Thus, the N- and C-termini of
CdiAUPEC536 can be tracked simultaneously using the appropriate
fluorescently labeled antibodies. Because the HA epitope was
inserted adjacent to the signal sequence (Fig. 1A), we first
examined surface expression of HA-CdiAUPEC536 by whole-cell
immunoblot to confirm that the modified exoprotein is still
secreted. Cells were incubated with fluorescent anti-HA antibodies
under conditions that do not permeabilize the outer membrane
based on staining for a periplasmic marker and then blotted onto
a nitrocellulose membrane (Fig. S1A). A strong fluorescent signal
was detected from cells expressing HA-CdiAUPEC536, but only
background fluorescence was observed from cells expressing
untagged CdiAUPEC536 or control CDI- cells carrying an empty
cosmid vector (Fig. 1B). The HA signal was sensitive to treatment
with proteinase K (Fig. 1B), consistent with epitope exposure on
the cell surface. However, to conclusively determine if the
immunoblot procedure only detects cell-surface antigens, we
repeated the analysis using antibodies to maltose-binding protein
(MBP), which is localized to the periplasm [19]. MBP was not
detected under the original immunoblot conditions, but a strong
signal was obtained when the cells were permeabilized with Triton
X-100 (Fig. S1A). Notably, the MBP signal was insensitive to
proteinase K, indicating that periplasmic and presumably
cytoplasmic antigens are protected from the protease (Fig. S1A).
Thus, fixation conditions can be controlled to differentiate
between surface exposed and internal antigens. We repeated this
analysis using polyclonal antibodies to CdiA-CTUPEC536 and
found that the toxin domain was present on the surface of inhibitor
cells expressing either HA-tagged or untagged CdiAUPEC536
(Fig. 1B).
CdiAUPEC536 is Delivered onto the Surface of Target Cells
Having established that HA-CdiAUPEC536 is secreted, we next
tested its inhibition activity in growth competition assays. Inhibitor
cells expressing HA-CdiAUPEC536 were incubated with target E.
coli cells in shaking broth cultures, and the number of viable target
cells were quantified. After four hours of co-culture with HA-
CdiAUPEC536 inhibitors, target cell counts decreased ,100-fold,
whereas CDI- mock inhibitor cells carrying the cosmid vector did
not inhibit target cell growth (Fig. S2). Moreover, HA-CdiAU-
PEC536 inhibited growth to the same extent as wild-type
CdiAUPEC536 (Fig. S2), demonstrating that the HA-tagged effector
protein is fully functional in CDI. We examined the co-cultures
with fluorescence microscopy to determine if CdiA-associated
antigens are transferred to target cells during CDI. In these
experiments, target cells were labeled with the red fluorescent
protein DsRed to differentiate them from unlabeled CDI+
inhibitor cells. Cell surfaces were stained with fluorescein-labeled
antibodies to CdiA-CTUPEC536, which revealed toxin antigen on
many cells in the co-culture including a large proportion of target
cells (Fig. 2A). CdiA-CTUPEC36 immunostaining was specific with
virtually no signal detected in co-cultures containing CDI- mock
inhibitor cells (Fig. 2A). All of the CdiA-CTUPEC536 antigen could
be removed with proteinase K treatment prior to antibody staining
(Fig. 2A), indicating that the toxin domain is exposed on the
surface of target cells. Co-cultures containing HA-CdiAUPEC536
inhibitor cells also showed similar transfer of CdiA-CTUPEC536
toxin antigen onto target bacteria (Fig. 2A). Somewhat un-
expectedly, immunostaining for the N-terminal HA epitope
revealed that this antigen is also delivered to the surface of target
cells (Fig. 2A). HA epitope staining was specific with no signal
detected in co-cultures containing cells that express untagged
CdiAUPEC536 (Fig. 2A). Together, these experiments demonstrate
that both the N-terminal and C-terminal regions of CdiAUPEC535
are transferred onto the surface of target cells.
CDI Toxin Delivery
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Figure 1. CdiAUPEC536 and HA-CdiAUPEC536 are exported to the cell surface. A) Schematic of the CdiAUPEC536 exoprotein depicting the
locations of the inserted N-terminal hemagglutinin (HA) epitope tag and the CdiA-CT region (residues Val3016– Ile3242) used to generate anti-CdiA-
CTUPEC536 polyclonal antibodies. Regions corresponding to the secretion signal sequence and the toxic tRNase domain are indicated. The vertical
VENN sequence demarcates the N-terminal margin of the variable CdiA-CT sequence. Residue numbers are shown by the scale bar below. B) Whole-
cell immunoblot analysis of E. coli cells expressing CdiAUPEC536 and HA-CdiAUPEC536. Cells expressing HA-CdiAUPEC536 (HA-CdiA), CdiAUPEC536 (CdiA) or
no effector protein (CDI-) were fixed without permeabilization and stained with anti-HA or anti-CdiA-CTUPEC536 (anti-CdiA-CT) antibodies. Where
indicated, cells were treated with proteinase K (proK) prior to fixation. Stained cells were spotted onto nitrocellulose membrane and analyzed with an
Odyssey infrared imager.
doi:10.1371/journal.pone.0057609.g001
CDI Toxin Delivery
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Our previous studies have shown that CdiA fragments are
released from inhibitor cells [2]. Soluble CdiA fragments have no
growth inhibition activity but could bind to cells non-specifically
and account for the fluorescent signal observed on target bacteria.
Therefore, we tested whether CdiAUPEC536 delivery is influenced
by the level of BamA receptor on target cells, reasoning that only
BamA-dependent transfer is relevant to the CDI pathway. Co-
culture and immunofluorescence experiments were repeated with
target cells that carry the bamA101 mutation, which reduces BamA
surface expression approximately five-fold [9]. Quantification of
bamA101 target cells with HA and CdiA-CTUPEC536 antigens on
their surface showed that CdiAUPEC536 delivery was reduced two-
to three-fold compared to bamA+ target cells (Figs. 2B & 2C).
Complementation of bamA101 cells with a plasmid expressing
BamA doubled the number of cells with CdiA-CTUPEC536 surface
staining, confirming that reduced CdiAUPEC536 delivery is due to
low BamA levels. Together, these data indicate that delivery of
CdiAUPEC536 to the surface of target cells is BamA-dependent.
CdiA-CTUPEC536 is Translocated into the Cytoplasm of
Target Cells during CDI
We next sought to detect CdiA-derived antigens inside target
bacteria. Control experiments using antibodies to periplasmic
MBP showed that internal antigens are only detectable when cells
are permeabilized with EDTA and lysozyme treatment (Fig. S1B).
We applied the EDTA/lysozyme procedure to CDI co-cultures
and observed diffuse CdiA-CTUPEC536 staining of both inhibitor
and target cells (Fig. 3A). This staining was specific with no signal
detected from either CDI- cells using anti-CdiA-CT antibodies
(Fig. 3A) or CdiA+ cells using anti-HA antibodies (Fig. 3B).
Because there is significant CdiA-CTUPEC536 antigen on cell
surfaces (see Fig. 2A), the signal from permeabilized cells likely
represents the sum of both surface and internal antigens.
Therefore, to specifically visualize internal CdiA-CTUPEC536, we
removed surface antigen with proteinase K treatment and then
permeabilized the cells for immunostaining. Using the protease/
permeabilization protocol, we found that virtually all inhibitor cells
Figure 2. CdiAUPEC536 is transferred to the surface of target cells. A) Immunofluorescence microscopy of CDIUPEC536 co-cultures. Non-
fluorescent inhibitor cells (expressing either CdiAUPEC536 or HA-CdiAUPEC536) were mixed with red fluorescent target cells (2:1 inhibitor-to-target ratio)
for 1 h, then analyzed by fluorescence microscopy using anti-CdiA-CTUPEC536 (anti-CdiA-CT) or anti-HA antibodies as described in Methods. Green
fluorescence is indicative of anti-CdiA-CT and anti-HA staining of cell surfaces. Inhibitor cells in the CDI- panel carry an empty vector without a CDI
system. Where indicated (+), samples were treated with proteinase K prior to fixation, but cells were not permeabilized. B) Transfer of CdiA-CTUPEC536
antigen to target cells. The percentage of bamA+ and bamA101 target cells with CdiA-CTUPEC536 antigen was quantified after one and two hours of co-
culture with CdiAUPEC536 inhibitor cells. The bamA101 allele was complemented with plasmid pBamA (corresponding to pDAL950 in Table 1). C)
Transfer of HA antigen to target cells. Quantifications in panels B and C were determined by analysis of 150 target cells from two independent
experiments. The reported values represent the average 6 SEM.
doi:10.1371/journal.pone.0057609.g002
CDI Toxin Delivery
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and approximately 30% of the target cells contain internal CdiA-
CTUPEC536 antigen (Fig. 3A). The HA-CdiAUPEC536 effector
protein delivered CdiA-CTUPEC536 antigen to targets at a level
similar to untagged CdiAUPEC536 (Fig. 3A), indicating that the N-
Table 1. Bacterial strains and plasmids used in this study.
Strain or plasmid Genotype or descriptiona Reference/Source
Strains
EPI100 F- mcrA D(mrr-hsdRMS-mcrBC) w80dlacZDM15 DlacX74 recA1 Epicentre
endA1 araD139 D(ara, leu)7697 galU galK - rpsL nupG, StrR
DY378 W3110 lcI857 D(cro-bioA) [30]
MC4100 F- araD139 D(argF-lac)U169 rpsL150 relA1 flbB5301 deoC1 [35]
ptsF25 rbsR, StrR
JCM158 F- D(argF-lac)U169 rpsL150 relA1 flbB5301 deoC1 ptsF25 [36]
rbsR, StrR
TT23216 Salmonella enterica strain containing chloramphenicol John Roth
acetyltransferase gene (cat), CmR
UPEC 536 Human uropathogenic E. coli isolate [37]
JW3994 F- D(araD-araB)567 DlacZ4787(::rrnB-3) rph-1 D(rhaD- [38]
rhaB)568 DmalE730::kan hsdR514, KanR
DL4259 MC4100 l640-13 PpapIB-gfp-mut3 This study
DL5562 JCM158 Dwzb::kan, KanR [9]
DL5564 JCM158 Dwzb [9]
DL5622 JCM158 Dwzb bamA101::kan, KanR [9]
DL6105 E. coli EC93 DcdiA-CT/DcdiI [5]
CH2016 X90 (DE3) Drna DslyD::kan, KanR [33]
CH8251 MC4100 rifr (spontaneous rifampicin-resistance), StrR RifR This study
CH9122 MC4100 rifr Dwzb bamA101::kan, StrR RifR KanR This study
CH9634 MC4100 rifr Dwzb::kan, StrR RifR KanR This study
Plasmids
pWEB-TNC Cosmid cloning vector, CmR AmpR Epicentre
pDsRed-Express2 pUC19 derivative encoding DsRed, AmpR Clontech
pBR322 cloning vector, AmpR TetR [39]
pCH70 pBluescript with kan cassette, AmpR, KanR [28]
pKSS pBluescript with pheS* counter-selectable marker, AmpR [29]
pKSS-Kan pKSS with kan cassette from pCH70, AmpR, KanR This study
pZS21-bamA pZS21 expressing BamA, KanR [40]
pDAL660D1-39 pWEB-TNC containing 16,734 bp cdiBAI sequence from [2]
E. coli EC93
pDAL672 plac-DsRed, AmpR [2]
pDAL852 pBR322 expressing the cdiI393722 immunity gene, AmpR [1]
pDAL866 pWEB-TNC::cdiBAIUPEC536, CmR AmpR [8]
pDAL878 pDAL660D1-39 with deletion of cdiA-CTEC93/cdiIEC93 region This study
(CDI-), CmR
pDAL879 Cosmid expressing chimeric CdiAEC93-CTo1
EC93 protein, CmR [5]
pDAL903 pWEB-TNC::cdiBAHAIUPEC536; encodes HA-CdiAUPEC536 effector This study
protein, CmR AmpR
pDAL950 pZS21-bamA with chloramphenicol resistance cassette, CmR This study
pCH9817 pTrc-DsRed, AmpR This study
pCH10323 Cosmid expressing chimeric CdiAEC93-CT393722 protein, CmR This study
pCH10412 pKSS-Kan with cdiAEC93 homology regions cloned upstream This study
and downstream of kan-pheS*, AmpR, KanR
aAbbreviations: AmpR, ampicillin resistant; CmR, chloramphenicol resistant; KanR, kanamycin resistant; RifR, rifampicin resistant; StrR, streptomycin resistant.
doi:10.1371/journal.pone.0057609.t001
CDI Toxin Delivery
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terminal HA tag does not adversely affect CdiA-CTUPEC536
translocation. We used the same fixation regimen to determine
whether the N-terminal HA epitope is also internalized by target
cells. Although there was abundant HA epitope detected on cells
in the co-culture, this signal was ablated by proteinase K treatment
(Fig. 3B), strongly suggesting that all of the HA peptide is surface
exposed. These data indicate that the N-terminal HA epitope
remains on the target cell surface, whereas the CdiA-CTUPEC536
toxin is internalized.
CdiA-CT Translocation into Target Cells is a General
Feature of CDI
CDI systems deploy a variety of toxins with diverse sequences,
all of which must be efficiently transported into target bacteria.
Therefore, we sought to visualize the delivery of another distinct
CDI toxin into E. coli cells. We showed previously that the CdiA-
CT393722 toxin from Dickeya dadantii 3937 is a non-specific DNase
that degrades plasmid DNA in vitro [1]. We reasoned that this
toxin should alter target cell DNA, which could be visualized by
DAPI staining and microscopy. The CDI system from D. dadantii
Figure 3. CdiA-CTUPEC536 is delivered into target cells. A) Anti-CdiA-CTUPEC536 immunofluorescence microscopy of CDIUPEC536 co-cultures. Non-
fluorescent inhibitor cells expressing either CdiAUPEC536 (CdiA) or HA-CdiAUPEC536 (HA-CdiA) were mixed with red fluorescent target cells (2:1 inhibitor-
to-target ratio) for 1 h. Cells were then fixed and permeabilized for fluorescence microscopy using anti-CdiA-CTUPEC536 (anti-CdiA-CT) antibodies as
described in Methods. Green fluorescence is indicative of anti-CdiA-CT immunostaining. Where indicated (+), cells were treated with proteinase K
prior to fixation. The histogram quantifies the percentage of target cells (average 6 SEM) with surface and internal CdiA-CTUPEC536 antigen staining.
At least 150 target cells from two independent experiments were scored for the quantification of CdiA delivery. B) Anti-HA epitope
immunofluorescence microscopy of CDIUPEC536 co-cultures. Co-culture conditions and sample preparation was as described in panel A except that
anti-HA antibodies were used for immunofluorescence. Green fluorescence is indicative of anti-HA immunostaining. Where indicated (+), cells were
treated with proteinase K prior to fixation.
doi:10.1371/journal.pone.0057609.g003
CDI Toxin Delivery
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e57609
3937 does not target E. coli [1]. Therefore, we replaced the CdiA-
CT of E. coli CdiAEC93 with the CdiA-CT393722 toxin to generate
a chimeric effector protein capable of delivering the DNase into E.
coli cells. We first tested the CdiAEC93-CT393722 chimera to
determine whether it is active in CDI. CDI393722 inhibitor cells
were mixed with target cells at a 1:1 ratio and incubated in shaking
broth cultures. After four hours of co-culture, the number of viable
target cells decreased ,1,000-fold (Fig. 4A). In contrast, target
cells carrying a plasmid-borne copy of the cdiI393722 immunity
gene grew unimpeded (Fig. 4A), indicating that the grafted CdiA-
CT393722 toxin is responsible for growth inhibition. To visualize
DNase activity in target cells, we repeated the co-culture
experiments with GFP labeled inhibitor cells and DsRed labeled
targets and stained the cells with DAPI to visualize nucleoids.
Upon initial mixing, inhibitor and target cells both exhibited
similar nucleoid staining and morphology (Fig. 4B). However,
a fraction of target cells lost DAPI staining after four hours of co-
culture with CDI393722 inhibitor cells (Fig. 4B), consistent with the
degradation of genomic DNA. This loss of DAPI staining was
CDI-dependent (Fig. 4C), and target cells that express the
cdiI393722 immunity gene showed no changes in nucleoid
appearance during co-culture with inhibitors (Fig. 4D). Finally,
we tested whether DNase delivery was dependent upon BamA.
We repeated the growth competition experiments using an
inhibitor to target cell ratio of 1:100 and found that bamA101
targets were resistant to the chimeric CDI393722 system under
these conditions (Fig. 5A). Microscopic analysis showed that wild-
type bamA+ cells were more likely to lose cellular DNA (,45%
anucleate cells) compared to bamA101 targets (,20% anucleate
cells) after co-culture with CDI393722 inhibitors (Figs. 5B & 5C).
Together, these results indicate that CdiA-CT393722 is translo-
cated into E. coli in a BamA-dependent manner and that the toxin
destroys target cell genomic DNA to inhibit growth.
Discussion
The experiments presented here represent the first examination
of CdiA effector protein transfer between bacteria during contact-
dependent growth inhibition. We find that both the N-terminal
and C-terminal regions of CdiA are deposited onto the surface of
target cells. Although it is formally possible that only N- and C-
terminal CdiA fragments are transferred, the delivery of both
antigens is dependent upon BamA expression, strongly suggesting
that the entire effector protein is transferred to the surface of target
bacteria. We find that CdiA-CTs are translocated into target cells,
presumably into the cytoplasm where the nucleic acid target
molecules reside. In contrast, we did not detect N-terminal HA
epitope inside target bacteria, indicating that the N-terminus of
CdiA is not efficiently internalized. Presumably, some portion of
the CdiA-CT is cleaved prior to translocation, but it is still unclear
how much of the CdiA protein is transported into the target cell
cytoplasm. Biochemical analysis indicates that the tRNase activity
of CdiAUPEC536 is contained within the C-terminal 145 residues,
and this fragment is sufficient to inhibit growth when expressed
inside E. coli cells [8]. These observations indicate that at
a minimum the extreme C-terminal tRNase domain must be
translocated into target cells during CDI. We note that the CdiA-
CTUPEC536 region appears to be comprised of two functional
domains, the C-terminal tRNase domain and an N-terminal
region of unknown function [8]. We suspect that the N-terminal
region that immediately follows the VENN motif facilitates
translocation of the C-terminal tRNase domain through the target
cell envelope, but this hypothesis remains to be rigorously tested.
CdiA and CdiB are members of the two-partner secretion
(TPS) protein family, which together with the related auto-
transporter systems constitute the type V secretion systems of
Gram-negative bacteria. TPS systems encode two proteins:
TpsB partners are outer membrane b-barrel proteins and the
secreted TpsA partners are large, hemagglutinin-repeat contain-
ing exoproteins. [20] The filamentous hemagglutinin (FHA)/
FhaC proteins from Bordetella species and the HMW1/2 proteins
of Haemophilus influenzae serve as paradigms for TPS protein
export and assembly onto the outer membrane. Although the
FHA and HMW1 TpsA proteins are related to CdiA, they do
not appear to contain toxic effector domains and instead
function as adhesins. Both FHA and HMW1 adhesins are held
in the outer membrane through non-covalent associations with
their TpsB protein partner. However, the orientation of TpsA
protein appears to be variable. Based on epitope accessibility
studies, FHA is predicted to interact with FhaC through its N-
terminus, thus projecting the C-terminus away from the cell
surface [21]. In contrast, HMW1 is assembled in the opposite
orientation, allowing the N-terminal adhesin domain to be
projected outward [22,23]. Because CdiA is transferred between
bacteria, the experiments described here are unable to un-
ambiguously determine the orientation of CdiA on the inhibitor
cell surface. The entire CdiA molecule appears to be transferred
to target cells, and thus either orientation should be feasible, as
long as the BamA-binding region of CdiA is accessible to its
ligand. The BamA-binding domain of CdiA is unknown, but is
presumably N-terminal to the variable CdiA-CT toxin region.
Localization of the BamA-binding region on CdiA is one
approach that may suggest a model for exoprotein topology in
the outer membrane of inhibitor cells. Alternatively, antibody
accessibility studies similar to those performed with FHA should
be informative if the transfer of CdiA between inhibitor cells
could be prevented.
CDI systems deploy toxins that are similar in activity to colicins
and other bacteriocins. Colicins are soluble protein toxins that
specifically target E. coli and a few closely related enterobacteria
[17]. In general, colicins have a conserved architecture comprised
of an N-terminal translocation domain, a central receptor-binding
domain, and a C-terminal toxin domain [24]. The receptor-
binding domain interacts with specific b-barrel proteins on the
surface of susceptible bacteria, and then the translocation domain
exploits either the Tol or Ton import systems to cross the outer
membrane. The receptor-binding domain is thought to remain at
the cell surface while the toxin domain is processed and released
into the cytoplasm [25,26]. A similar process probably occurs
during CDI, with only the C-terminal region of CdiA transported
into target bacteria. However, CdiA exoproteins are clearly
distinct from colicins and do not rely on the Tol or Ton systems for
import [2,9]. Perhaps the most striking difference is that CDI
requires direct cell-to-cell contact to deliver toxins – soluble CdiA
fragments containing the CdiA-CT region have no effect on cell
growth [2]. The requirement for cell-cell contact is not understood
and is somewhat perplexing given that the entire CdiA molecule is
transferred to the surface of target cells. Perhaps the entire CdiA
molecule is required for toxin translocation. The N-terminus of
CdiA may contain a domain(s) necessary for toxin translocation
into target cells. This could include the CdiA cleavage site or
a protease domain that is required for protein processing. It is
remarkable that multiple pathways exist for the import of relatively
large toxin domains through the Gram-negative cell envelope. We
are currently identifying additional genes required for CDI, which
will likely inform mechanistic models of CDI toxin import.
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Materials and Methods
Plasmids and Bacterial Strains
All plasmids and E. coli strains used in this study are listed in
Table 1. Bacteria were grown in either LB medium (1% NaCl, 1%
tryptone, 0.5% yeast extract) or tryptone broth (TB) (1% tryptone,
0.5% NaCl) supplemented with 10 mM MgSO4. Antibiotics were
used at the following concentrations unless otherwise indicated:
ampicillin (Amp), 100 mg/mL; chloramphenicol (Cm), 34 mg/mL;
kanamycin (Kan), 50 mg/mL; streptomycin (Str), 50 mg/mL; and
rifampicin (Rif), 200 mg/mL.
Cosmid pDAL866 constitutively expresses the cdiBAI gene
cluster from UPEC 536 [8]. The HA epitope coding sequence was
introduced between the codons for Ala32 and Val33 of UPEC 536
cdiA using overlapping extension PCR (OE-PCR) [27]. Fragments
of cdiAUPEC536 were amplified using oligonucleotide pairs 2051/
2064 and 2065/2052, and the two PCR products were joined by
a second amplification using primers 2051/2052 (Table S1). The
resulting product was digested with NsiI and StuI restriction
endonucleases and ligated to NsiI/StuI-digested pDAL866 to
generate cosmid pDAL903. Cosmid pDAL878 is a CDI- de-
rivative of pDAL660D1-39 [2] in which the cdiA-CTEC93/cdiIEC93
toxin/immunity region has been deleted. Primers 1527/1663 were
used to amplify a DNA fragment from strain DL6105 [5] and the
resulting product was digested with SphI/AvrII and ligated to
SphI/AvrII-digested cosmid pDAL660D1-39.
The chimeric CdiAEC93-CT393722 CDI system (cosmid
pCH10323) was constructed in several steps. First, the kanamycin
resistance cassette from plasmid pCH70 [28] was amplified with
primers kan-Hind-for/kan-Eco-rev and ligated into HindIII/
EcoRI-digested plasmid pKSS [29] to generate pKSS-Kan.
Regions flanking the cdiA-CTo1
EC93 sequence on cosmid pDAL879
[5] were then amplified with primer pairs EC93-Kpn-for/EC93-
Hind-rev and EC93o1-Bam-for/EC93o1-Sac-rev. The PCR prod-
Figure 4. The CdiA-CT393722 DNase is delivered into E. coli cells. A) The chimeric EC93-Dd3937 CDI system is functional. Mock inhibitors (CDI-)
or CDI3937 cells were co-cultured at a 1:1 ratio with target bacteria that carry plasmid pBR322 (cdiI-) or pDAL852 (cdiI393722). Co-cultures were sampled
at the indicated times and viable target cells quantified as colony forming units (CFU) per mL. Reported values are the average 6 SEM for three
independent experiments. For panels B, C and D, inhibitor cells were labeled with GFP (green) and targets with DsRed (red) to differentiate the two
cell populations by fluorescence microscopy. Competitions were conducted as described for panel A, and cells were stained with DAPI to visualize
DNA. B) Inhibitor cells expressing CdiA-CT393722 were co-cultured with cdiI- targets, C) Mock inhibitors (CDI-) were co-cultured with cdiI- targets. D)
Inhibitors expressing CDI3937 were co-cultured with targets expressing CdiI393722 immunity.
doi:10.1371/journal.pone.0057609.g004
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ucts were ligated sequentially into pKSS-Kan using KpnI/HindIII
and BamHI/SacI restriction sites. The large KpnI/SacI fragment
from the resulting plasmid (pCH10412) was gel-purified and
electroporated together with cosmid pDAL879 into E. coli DY378
cells expressing the phage l Red proteins as described [30].
Transformants containing recombined cosmids, which contain the
kanR-pheS* cassette in place of the cdiA-CTo1
EC93 toxin sequence,
were selected on LB-agar supplemented with 50 mg/mL kanamy-
cin. The resulting pCdiA-CT/pheS* cosmid was used for allelic
exchange with cdiA-CT393722/cdiI393722 as follows. The cdiA-
CT393722/cdiI393722 coding region was amplified with primers
3937-CT2-for/3937-cdiI2-rev. An upstream cdiAEC93 homology
region was amplified with primer 1527 and 3937CT2-chim-rev;
and a downstream homology region amplified with primers
3937CT2-chim-for and 2368. The three PCR products were
combined by overlapping extension-PCR (OE-PCR) [27] using
oligonucleotides 1527/2368. The final product (100 ng) was
electroporated together with 300 ng of cosmid pCdiA-CT/pheS*
into E. coli DY378 and cells carrying the recombinant cosmid
(pCH10323) were selected on YEG-agar (0.5% yeast extract, 1%
NaCl, 0.4% glucose, 15 g agar/L) supplemented with 33 mg/mL
chloramphenicol and 10 mM D/L-p-chlorophenylalanine.
The kanamycin-resistance cassette of pZS21-bamA (Kim et al.,
2007) was replaced with a chloramphenicol acetyltransferase (cat)
marker. The cat gene from Salmonella enterica TT23216 was
amplified using oligonucleotides 2596/2597, digested with SacI/
AatII and ligated to SacI/AatII-digested pZS21-bamA to generate
plasmid pDAL950. The coding sequence for DsRed-Express2 was
excised from plasmid DsRed-Express2 (Clontech) using NcoI/
SpeI digestion, and the fragment subcloned into pTrc(DAS) [5] to
generate plasmid pCH9817. Plasmid pDAL852 is a pBR322
derivative that expresses the cdiI393722 gene from the tet promoter
[1]. The identities of all plasmid and cosmid constructs were
confirmed by DNA sequencing.
Figure 5. DNase delivery is dependent upon the BamA receptor. A) bamA101 target cells are resistant to the chimeric EC93-Dd3937 CDI
system. Mock inhibitors (CDI-) or CDI3937 cells were co-cultured with bamA+ cells or bamA101 cells at a 1:100 inhibitor to target ratio. Cultures were
sampled at the indicated times and viable target cells quantified as colony forming units (CFU) per mL. Reported values are the average 6 SEM for
three independent experiments. B) Visualization of DNase delivery. Competitions were conducted as described for panel A, but inhibitors were
labeled with GFP (green) and targets with DsRed (red) to differentiate the two cell populations by fluorescence microscopy. Cells were stained with
DAPI to visualize DNA. C) Quantification of anucleate target cells. The percentage of anucleate target cells (defined as cells lacking DAPI staining) was
determined by inspection of random microscopy fields. Two independent co-cultures were analyzed and between 186–260 target cells were scored
for each competition. Values represent the average 6 SEM.
doi:10.1371/journal.pone.0057609.g005
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Growth Competition Assays
Inhibitor cells carrying CDI cosmids [pWEB-TNC (mock
CDI-), pDAL878 (mock CDI-), pDAL866 (CdiAUPEC536),
pDAL903 (HA-CdiAUPEC536) or pCH10323 (CdiAEC93-
CT393722)] were mixed with E. coli target cells (JCM158 Dwzb
or MC4100 Dwzb derivatives) at various ratios and incubated in
baffled flasks with shaking (250 rpm) at 37uC. Viable target cells
were quantified as colony forming units (CFU) per mL by serial
dilution onto LB agar plates supplemented with the appropriate
antibiotic. For fluorescence microscopy of CDI co-cultures, target
cells carried either plasmid pDAL672 or pCH9817, which express
DsRed from the lac and trc promoters (respectively). E. coli DL4259
cells carrying pCH10323 were used as inhibitors for visualization
of CdiA-CT393722 DNase activity during CDI. DL4259 contains
the phage l640-13 lysogen, which constitutively expresses gfp-mut3
under control of the papIB promoter [31,32].
Antiserum Preparation and Whole-cell Immunoblotting
Polyclonal antiserum against residues Val3016– Ile3242 of
CdiAUPEC536 was raised in rabbits (CoCalico Biologicals) [8].
Non-specific antibodies were removed by incubation with
carbonyldiimidazole-activated agarose beads linked to soluble
protein from E. coli strain CH2016 [33]. Briefly, protein-linked
beads were resuspended in 0.5 mL of antiserum and the slurry
mixed by rotation for 1 h at room temperature and an additional
8 h at 4uC. This process was repeated at least four times with fresh
beads. Antiserum used to detect internal antigens via immunoflu-
orescence microscopy was further purified by incubation with
insoluble E. coli cell material. All adsorbed antisera were stored at
4uC with 0.2% sodium azide as preservative. For whole-cell
immunoblotting, cells were grown to mid-log phase in TB
medium, collected by centrifugation and fixed with 4% formal-
dehyde in phosphate buffered saline (PBS, pH 7.4) for 15 min.
Fixation reactions were quenched with 100 mM glycine (pH 7.4),
and the cells were permeabilized with 0.1% Triton X-100 and
0.1% sodium citrate in PBS for 15 min. Cells were incubated with
antibodies anti CdiA-CTUPEC536 antiserum, mouse monoclonal
anti-HA antibody (Covance), or mouse monoclonal anti-maltose
binding protein (New England Biolabs)] in PBS supplemented
with 1% bovine serum albumin (BSA). After washing with PBS,
cells were incubated with goat anti-rabbit IRdyeH800 or goat anti-
mouse IRdyeH680 secondary antibodies (Licor). Cells were washed
three times in PBS, spotted onto nitrocellulose membranes, dried
for 1 h and visualized with the Odyssey Infrared Imaging System
(Licor).
Immunofluorescence Microscopy
Competition co-cultures were collected and fixed with formal-
dehyde as described above. Where indicated, cells were treated
with proteinase K (100 microgram/mL) for 30 min at 37uC prior
to fixation. Cells mixtures were washed with PBS and resuspended
in PBS supplemented with 1% BSA and purified rabbit anti-CdiA-
CT antiserum or mouse monoclonal anti-HA antiserum (HA.11,
Covance). After incubation for 30 min, cells were washed with 1%
BSA in PBS and resuspended in 1% BSA in PBS supplemented
with the appropriate fluorescent secondary antibody [goat anti-
rabbit AlexaFluorH488, goat anti-mouse AlexaFluorH488, or goat
anti-rabbit AlexaFluorH488 and goat anti-mouse AlexaFluorH568
secondary antibodies (Invitrogen)] for 30 min on ice. After
washing, cells were resuspended in PBS supplemented with
0.2% sodium azide, spotted onto poly-D-lysine coated glass slides
and sealed with FluoroGel II (Electron Microscope Sciences).
Samples were visualized using an Olympus BX51 microscope,
Omega filters XF116-2 (for EGFP) and XF103-2 (for Ds-Red) and
an Optronics (Goleta, CA) camera (gain = 16 and 500 ms
fluorescence exposure). Overlaid images were adjusted for
brightness and contrast using Adobe Photoshop CS2. GFP images
were layered over Ds-Red images at 75% opacity. GFP signal
brightness was adjusted to –30 and contrast adjusted to +30,
images flattened, and curves adjusted to 110 input and 250 output.
For visualization of in vivo DNase activity, fixed cells were stained
with SlowFade gold solution with DAPI (Invitrogen) supplemented
with 0.1% Triton X-100. Camera settings were as follows:
brightfield imaging: 30 ms exposure, gain = 2; DAPI staining:
200 ms exposure, gain = 2; DsRed: 1 s exposure, gain = 10; and
GFP: 1 s exposure, gain = 10. Images were processed using the
GIMP image enhancement software and altered for contrast
enhancement opacity for image overlays.
For detection of internal antigens, cell fixation and permeabi-
lization was conducted as described [34] with the following
modifications. Where indicated, cells were treated with 100 mg/
mL proteinase K at 37uC for 30 min prior to fixation. Cells were
fixed in 2.6% formaldehyde, 0.04% glutaraldehyde in 32 mM
sodium phosphate (pH 7.4) for 10 min at room temperature and
50 min on ice. After washing with PBS, cells were resuspended in
50 mM glucose, 20 mM Tris-Cl (pH 7.5), 10 mM EDTA
supplemented with 0.02 mg/mL lysozyme. The cell suspension
was spotted onto a poly-D-lysine-coated slide and incubated for
10 min. Unbound cells were removed with three water rinses and
the slides air-dried for 45 min. After rehydration in PBS for 4 min,
samples were incubated with 1% Blocking Reagent (Invitrogen) in
PBS, then stained with either rabbit anti-CdiA-CT or mouse anti-
HA antibodies. After washing, cells were incubated with goat anti-
rabbit IgG or goat anti-mouse IgG secondary antibodies
conjugated to horseradish peroxidase. Samples were washed with
PBS and incubated in amplification buffer (Invitrogen) containing
0.0015% hydrogen peroxide and 1:1000 tyramide Alexa-
FluorH488 (Invitrogen) for 5 min. Slides were washed with PBS,
sealed with a drop of FluoroGel II (Electron Microscope Sciences)
and coverslip, then analyzed with fluorescence microscopy as
described above for surface antigens.
Supporting Information
Figure S1 Immunodetection of cell-surface and internal
antigens. A) Whole-cell immunoblot for maltose-binding protein
(MBP). Wild-type E. coli malE+ (MBP+) and DmalE (MBP-) cells
were incubated with anti-MBP antibodies and spotted onto
nitrocellulose membrane for fluorescence imaging as described
in Methods. Where indicated (+), samples were treated with
proteinase K (proK) to remove cell-surface antigens, and/or
Triton X-100 (PERM) to permeabilize the cells. B) Immunoflu-
orescence microscopy of MBP. Wild-type E. coli malE+ (MBP+)
and DmalE (MBP-) cells were analyzed by fluorescence microscopy
using anti-MBP antibodies. Where indicated (+), samples were
treated with proteinase K (proK) to remove cell-surface antigens,
and/or lysozyme and EDTA (PERM) to permeabilize the cells.
Together, these control experiments demonstrate that internal/
periplasmic antigens are not degraded by proteinase K treatment
and that internal antigens are only detected when cells have been
permeabilized.
(TIF)
Figure S2 HA-CdiAUPEC536 is fully functional in CDI.
Inhibitor E. coli cells carrying cosmids pDAL866 (CdiAUPEC536),
pDAL903 (HA-CdiAUPEC536), or pWEB-TNC (CDI- vector
control) were co-cultured with target cells (JCM158 Dwzb::kan).
Viable target cells were quantified as colony forming units (CFU)
per mL by plating co-cultures onto LB agar supplemented with
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kanamycin. Values represent the average 6 SEM for at least two
independent experiments.
(TIFF)
Table S1 Oligonucleotides used in this study.
(DOCX)
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